LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Publisher: Taylor & Francis
Languages: English
Types: Article
Subjects: RS, RM

Classified by OpenAIRE into

mesheuropmc: lipids (amino acids, peptides, and proteins)
The present article is aimed to outline the current state of knowledge regarding the effects of lipoprotein(a) (Lp(a)) on cardiovascular disease (CVD) risk by summarizing the recent results of studies, meta-analyses and systematic reviews. The literature supports the predictive value of Lp(a) on CVD outcomes, although the effect size is modest. Lp(a) would also appear to have an effect on cerebrovascular outcomes, with the effect appearing even smaller than that for CVD outcomes. Consideration of apolipoprotein apolipoprotein(a) (apo (a)) isoforms and LPA genetics in relation to the simple assessment of Lp(a) concentration may enhance improving clinical practice in vascular medicine. We also describe recent advances in Lp(a) research (including therapies) and highlight areas where further research is needed such as the measurement of Lp(a) and its involvement in additional pathophysiological processes.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
    • 2. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002;43:1363-79.
    • 3. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000.
    • 4. Rosenson RS, Brewer HB, Jr., Chapman MJ, Fazio S, Hussain MM, Kontush A, et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 2011;57:392-410.
    • 5. Banach M, Aronow WS, Serban M-C, Rysz J, Voroneanu L, Covic A. Lipids, blood pressure and kidney update 2015. Lipid health dis 2015;14:1.
    • 6. Colantonio LD, Bittner V, Reynolds K, Levitan EB, Rosenson RS, Banach M, et al. Association of Serum Lipids and Coronary Heart Disease in Contemporary Observational Studies. Circulation 2015: CIRCULATION AHA. 115.011646.
    • 7. Kucera M, Oravec S, Hirnerova E, Huckova N, Celecova Z, Gaspar L, et al. Effect of Atorvastatin on Low-Density Lipoprotein Subpopulations and Comparison Between Indicators of Plasma Atherogenicity A Pilot Study. Angiology 2014;65:794-9.
    • 8. Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, Davidson M, Rysz J, Banach M. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 2012;51:314-24.
    • 9. Utermann G. The mysteries of lipoprotein (a). Science 1989;246:904-10.
    • 10. Kamstrup PR. Lipoprotein (a) and ischemic heart disease - a causal association? A review. Atherosclerosis 2010;211:15-23.
    • 11. Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010;31:2844-53.
    • 12. Lippi G, Franchini M, Targher G. Screening and therapeutic management of lipoprotein (a) excess: review of the epidemiological evidence, guidelines and recommendations. Clin Chim Acta 2011;412:797-801.
    • 13. Hoover-Plow J, Huang M. Lipoprotein (a) metabolism: potential sites for therapeutic targets. Metabolism 2013;62:479-91.
    • 14. Boffa MB, Koschinsky ML. Update on lipoprotein (a) as a cardiovascular risk factor and mediator. Curr Atheroscler Rep 2013;15:1-10.
    • 15. Scanu A, Nakajima K, Edelstein C. Apolipoprotein (a): structure and biology. Front Biosci 2001;6:D546-54.
    • 16. Lamon-Fava S, Diffenderfer MR, Marcovina SM. Lipoprotein (a) metabolism. Curr Opin Lipidol 2014;25:189-93.
    • 17. Utermann G. Genetic architecture and evolution of the lipoprotein (a) trait. Curr Opin Lipidol 1999;10:133-42.
    • 18. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein (a) and increased risk of myocardial infarction. JAMA 2009;301:2331-9.
    • 19. Chasman DI, Shiffman D, Zee RY, Louie JZ, Luke MM, Rowland CM, et al. Polymorphism in the apolipoprotein (a) gene, plasma lipoprotein (a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis 2009;203:371-6.
    • 20. Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, et al. Genetic variants associated with Lp (a) lipoprotein level and coronary disease. New Engl J Med 2009;361:2518- 28.
    • 21. Enkhmaa B, Anuurad E, Zhang W, Tran T, Berglund L. Lipoprotein (a): genotypephenotype relationship and impact on atherogenic risk. Metab Syndr Relat Disord 2011;9:411-8.
    • 22. Helgadottir A, Gretarsdottir S, Thorleifsson G, Holm H, Patel RS, Gudnason T, et al. Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol 2012;60:722-9.
    • 23. Lamon-Fava S, Diffenderfer MR, Marcovina SM. Lipoprotein(a) metabolism. Curr Opin Lipidol 2014;25:189-93.
    • 24. Diffenderfer MR, Lamon-Fava S, Marcovina SM, Barrett PHR, Lel J, Dolnikowski GG, et al. Distinct metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein(a). Metabolism 2016;65:381-90.
    • 25. Kassner U, Schlabs T, Rosada A, Steinhagen-Thiessen E. Lipoprotein(a)--An independent causal risk factor for cardiovascular disease and current therapeutic options. Atherosclerosis Suppl 2015;18:263-7.
    • 26. Bos S, Yayha R, van Lennep JER. Latest developments in the treatment of lipoprotein (a). Curr Opin Lipidol 2014;25:452-60.
    • 27. Danesh J, Collins R, Peto R. Lipoprotein (a) and coronary heart disease meta-analysis of prospective studies. Circulation 2000;102:1082-5.
    • 28. Collaboration ERF. Lipoprotein (a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302:412.
    • 29. Genser B, Dias KC, Siekmeier R, Stojakovic T, Grammer T, Maerz W. Lipoprotein (a) and risk of cardiovascular disease--a systematic review and meta analysis of prospective studies. Clin Lab 2011;57:143-56.
    • 30. Craig WY, Neveux LM, Palomaki GE, Cleveland MM, Haddow JE. Lipoprotein (a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem 1998;44:2301-6.
    • 31. Jacobson TA, editor Lipoprotein (a), cardiovascular disease, and contemporary management. Mayo Clinic Proceedings; 2013: Elsevier.
    • 32. Smolders B, Lemmens R, Thijs V. Lipoprotein (a) and stroke a meta-analysis of observational studies. Stroke 2007;38:1959-66.
    • 33. Banach M, Bromfield S, Howard G, Howard VJ, Zanchetti A, Aronow WS, et al. Association of systolic blood pressure levels with cardiovascular events and all-cause mortality among older adults taking antihypertensive medication. Int J Cardiol 2014;176:219-26.
    • 34. Zanchetti A, Liu L, Mancia G, Parati G, Grassi G, Stramba-Badiale M, et al. Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence. J Hypertens 2014;32:1741-50.
    • 35. Denti L, Marchini L, Pasolini G, Baffoni MT, Ablondi F, Valenti G. Lipoprotein Lp(a) and cerebrovascular disease in the elderly: correlations with the severity of extracranial carotid atherosclerosis assessed by ultrasonography. Acta bio-medica de L'Ateneo parmense 1995;66:175-83.
    • 36. Kotani K, Shimohiro H, Adachi S, Sakane N. Relationship between lipoprotein(a), metabolic syndrome, and carotid atherosclerosis in older Japanese people. Gerontology 2008;54:361-4.
    • 37. Nave AH, Lange KS, Leonards CO, Siegerink B, Doehner W, Landmesser U, et al. Lipoprotein (a) as a risk factor for ischemic stroke: A meta-analysis. Atherosclerosis 2015;242:496-503.
    • 38. Langsted A, Kamstrup PR, Nordestgaard BG. Lipoprotein(a): fasting and nonfasting levels, inflammation, and cardiovascular risk. Atherosclerosis 2014;234:95-101.
    • 39. Langsted A, Varbo A, Kamstrup PR, Nordestgaard BG. Elevated Lipoprotein(a) Does Not Cause Low-Grade Inflammation Despite Causal Association With Aortic Valve Stenosis and Myocardial Infarction: A Study of 100,578 Individuals from the General Population. J Clin Endocrinol Metab 2015;100:2690-9.
    • 40. Erqou S, Thompson A, Di Angelantonio E, Saleheen D, Kaptoge S, Marcovina S, et al. Apolipoprotein (a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol 2010;55:2160-7.
    • 41. Sofi F, Marcucci R, Abbate R, Gensini GF, Prisco D. Lipoprotein (a) and venous thromboembolism in adults: a meta-analysis. Am J Med 2007;120:728-33.
    • 42. Toulis KA, Goulis DG, Mintziori G, Kintiraki E, Eukarpidis E, Mouratoglou S-A, et al. Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Repro Update 2011;17:741-60.
    • 43. Kamstrup PR, Nordestgaard BG. Elevated Lipoprotein(a) Levels, LPA Risk Genotypes, and Increased Risk of Heart Failure in the General Population. JACC Heart failure 2016;4:78- 87.
    • 44. Narverud I, Retterstøl K, Iversen PO, Halvorsen B, Ueland T, Ulven SM, et al. Markers of atherosclerotic development in children with familial hypercholesterolemia: A literature review. Atherosclerosis 2014;235:299-309.
    • 45. Baldassarre D, Tremoli E, Franceschini G, Michelagnoli S, Sirtori C. Plasma lipoprotein (a) is an independent factor associated with carotid wall thickening in severely but not moderately hypercholesterolemic patients. Stroke 1996;27:1044-9.
    • 46. Alonso R, Andres E, Mata N, Fuentes-Jiménez F, Badimón L, López-Miranda J, et al. Lipoprotein (a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol 2014;63:1982-9.
    • 47. Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J 2015:ehv157.
    • 48. Myśliwiec M, Walczak M, Małecka-Tendera E, Dobrzańska A, Cybulska B, Filipiak K, et al. Management of familial hypercholesterolemia in children and adolescents. Position paper of the Polish Lipid Expert Forum. J Clin Lipid 2014;8:173-80.
    • 49. Tziomalos K, Athyros VG, Wierzbicki AS, Mikhailidis DP. Lipoprotein a: where are we now? Curr Opin Cardiol 2009;24:351-7.
    • 50. Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010;31:2844-53.
    • 51. Schwartz J, Winters JL, Padmanabhan A, Balogun RA, Delaney M, Linenberger ML, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apheresis 2013;28:145-284.
    • 52. Leebmann J, Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)- hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 2013;128:2567-76.
    • 53. Thompson GR. Recommendations for the use of LDL apheresis. Atherosclerosis 2008;198:247-55.
    • 54. Jaeger BR, Richter Y, Nagel D, Heigl F, Vogt A, Roeseler E, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nature Clin Pract Cardiovasc Med 2009;6:229-39.
    • 55. Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, et al. Guidelines for the primary prevention of stroke a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:517-84.
    • 56. Kotani K, Sahebkar A, Serban MC, Ursoniu S, Mikhailidis DP, Mariscalco G, et al. Lipoprotein(a) levels in patients with abdominal aortic aneurysm: A systematic review and metaanalysis. Angiology 2016; doi: 10.1177/0003319716637792.
    • 57. Ooi EM, Watts GF, Chan DC, Pang J, Tenneti VS, Hamilton SJ, et al. Effects of Extended-Release Niacin on the Postprandial Metabolism of Lp(a) and ApoB-100-Containing Lipoproteins in Statin-Treated Men With Type 2 Diabetes Mellitus. Arterioscler Thromb Vasc Biol 2015;35:2686-93.
    • 58. Albers JJ, Slee A, O'Brien KD, Robinson JG, Kashyap ML, Kwiterovich PO, Jr., et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol 2013;62:1575-9.
    • 59. Artemeva NV, Safarova MS, Ezhov MV, Afanasieva OI, Dmitrieva OA, Pokrovsky SN. Lowering of lipoprotein(a) level under niacin treatment is dependent on apolipoprotein(a) phenotype. Atherosclerosis Suppl 2015;18:53-8.
    • 60. Lippi G, Targher G. Optimal therapy for reduction of lipoprotein (a). J Clin Pharma Ther 2012;37:1-3.
    • 61. Takagi H, Umemoto T. Atorvastatin decreases lipoprotein(a): a meta-analysis of randomized trials. Int J Cardiol 2012;154:183-6.
    • 62. Jansen AC, van Aalst-Cohen ES, Tanck MW, Trip MD, Lansberg PJ, Liem AH, et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med 2004;256:482-90.
    • 63. Seed M, Hoppichler F, Reaveley D, McCarthy S, Thompson GR, Boerwinkle E, et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. New Engl J Med 1990;322:1494-9.
    • 64. Hoover-Plow J, Huang M. Lipoprotein(a) metabolism: Potential sites for therapeutic targets. Metabolism 2013;62:479-91.
    • 65. Mullur R, Liu Y-Y, Brent GA. Thyroid hormone regulation of metabolism. Physiol Rev 2014;94:355-82.
    • 66. Samaha FF, McKenney J, Bloedon LT, Sasiela WJ, Rader DJ. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nature Clin Pract Cardiovasc Med 2008;5:497-505.
    • 67. Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Hegele RA, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013;381:40-6.
    • 68. Kotani K, Sahebkar A, Serban C, Andrica F, Toth PP, Jones SR, et al. Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients. Atherosclerosis 2015;242:87-96.
    • 69. Akaike M, Azuma H, Kagawa A, Matsumoto K, Hayashi I, Tamura K, et al. Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin Chem 2002;48:1454-9.
    • 70. Sheridan C. CETP inhibitors boost'good'cholesterol to no avail. Nature Biotechnol 2016;34:5-6.
    • 71. Lewis CE. Defining the Safety of Anacetrapib, a CETP Inhibitor, in Patients at High Risk for Coronary Heart Disease: the DEFINE study. Curr Cardiovasc Risk Rep 2011;5:109-12.
    • 72. Tsimikas S, Viney NJ, Hughes SG, Singleton W, Graham MJ, Baker BF, et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet 2015;386:1472-83.
    • 73. Romagnuolo R, Scipione CA, Boffa MB, Marcovina SM, Seidah NG, Koschinsky ML. Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor. J Biol Chem 2015;290:11649-62.
    • 74. Banach M, Rizzo M, Obradovic M, Montalto G, Rysz J, P Mikhailidis D, et al. PCSK9 inhibition-a novel mechanism to treat lipid disorders? Curr Pharmaceut Design 2013;19:3869- 77.
    • 75. Dragan S, Serban M-C, Banach M. Proprotein Convertase Subtilisin/Kexin 9 Inhibitors An Emerging Lipid-Lowering Therapy? J Cardiovasc Pharmacol Ther 2015;20:157-68.
    • 76. Ferdinand KC, Nasser SA. PCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a). Cardiovasc Drugs Ther 2015;29:295-308.
    • 77. Gaudet D, Kereiakes DJ, McKenney JM, Roth EM, Hanotin C, Gipe D, et al. Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am J Cardiol 2014;114:711-5.
    • 78. Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol 2014;63:1278-88.
    • 79. Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry U, Lin Y, et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: A systematic review and meta-analysis. Ann Intern Med. 2015;163:40-51.
    • 80. Li C, Lin L, Zhang W, Zhou L, Wang H, Luo X, et al. Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials. J Am Heart Assoc. 2015;4:e001937.
    • 81. Schultz O, Oberhauser F, Saech J, Rubbert-Roth A, Hahn M, Krone W, et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PloS One 2010;5:e14328.
    • 82. Chennamsetty I, Claudel T, Kostner KM, Trauner M, Kostner GM. FGF19 signaling cascade suppresses APOA gene expression. Arterioscler Thromb Vasc Biol 2012;32:1220-7.
    • 83. Rysz J, Gluba-Brzózka A, Mikhailidis DP, Banach M. Fibroblast growth factor 19- targeted therapies for the treatment of metabolic disease. Expert Opin Investig Drugs 2015;24:603-10.
    • 84. Serban M-C, Sahebkar A, Mikhailidis DP, Toth PP, Jones SR, Muntner P, et al. Impact of L-carnitine on plasma lipoprotein (a) concentrations: A systematic review and meta-analysis of randomized controlled trials. Sci Rep 2015;5:19188.
    • 85. Fukami K, Yamagishi S-i, Sakai K, Kaida Y, Yokoro M, Ueda S, et al. Oral L-Carnitine Supplementation Increases Trimethylamine-N-oxide but Reduces Markers of Vascular Injury in Hemodialysis Patients. J Cardiovasc Pharmacol 2015;65:289-95.
    • 86. Koeth RA, Wang Z, Levison BS, Buffa JA, Sheehy BT, Britt EB, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nature Med 2013;19:576-85.
    • 87. Wu W-K, Panyod S, Ho C-T, Kuo C-H, Wu M-S, Sheen L-Y. Dietary allicin reduces transformation of L-carnitine to TMAO through impact on gut microbiota. J Func Foods 2015;15:408-17.
    • 88. Sahebkar A, Serban C, Ursoniu S, Banach M. Effect of garlic on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled clinical trials. Nutrition 2016;32:33-40.
    • 89. Anuurad E, Boffa MB, Koschinsky ML, Berglund L. Lipoprotein (a): a unique risk factor for cardiovascular disease. Clin Lab Med 2006;26:751-72.
    • 90. McConnell JP, Guadagno PA, Dayspring TD, Hoefner DM, Thiselton DL, Warnick GR, et al. Lipoprotein (a) mass: a massively misunderstood metric. J Clin Lipidol 2014;8:550-3.
    • 91. Guadagno PA, Bellin EGS, Harris WS, Dayspring TD, Hoefner DM, Thiselton DL, et al. Validation of a lipoprotein (a) particle concentration assay by quantitative lipoprotein immunofixation electrophoresis. Clin Chim Acta 2015;439:219-24.
    • 92. Craig WY, Neveux LM, Palomaki GE, Cleveland MM, Haddow JE. Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem 1998;44:2301-6.
    • 93. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein (a) and Cardiovascular Disease: recent advances and future directions. Clin Chem 2003;49:1785-96.
    • 94. Lassman ME, McLaughlin TM, Zhou H, Pan Y, Marcovina SM, Laterza O, et al. Simultaneous quantitation and size characterization of apolipoprotein (a) by ultra performance liquid chromatography/mass spectrometry. Rapid Commun Mass Spectrom 2014;28:1101-6.
    • 95. Lanktree MB, Anand SS, Yusuf S, Hegele RA. Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein (a) in South Asians, Chinese, and European Caucasians. Circulation: Cardiovasc Genet 2010;3:39-46.
    • 96. Li Z, Li G, Zhou Y, Chen Z, Yang J, Zhang Y, et al. Lack of association between lipoprotein (a) genetic variants and subsequent cardiovascular events in Chinese Han patients with coronary artery disease after percutaneous coronary intervention. Lipid Health Dis 2013;12:127.
    • 97. Holvoet P. Oxidized LDL and coronary heart disease. Acta Cardiol 2004;59:479-84.
    • 98. Steinberg D. The LDL modification hypothesis of atherogenesis: an update. J Lipid Res 2009;50:S376-81.
    • 99. Tsimikas S, Mallat Z, Talmud PJ, Kastelein JJ, Wareham NJ, Sandhu MS, et al. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J Am Coll Cardiol 2010;56:946-55.
    • 100. Yamada S, Morishita R, Nakamura S, Ogihara T, Kusumi Y, Sakurai I, et al. Development of antibody against epitope of lipoprotein(a) modified by oxidation: evaluation of new enzyme-linked immunosorbent assay for oxidized lipoprotein(a). Circulation 2000;102:1639-44.
    • 101. Kotani K, Yamada S, Uurtuya S, Yamada T, Taniguchi N, Sakurabayashi I. The association between blood glucose and oxidized lipoprotein(a) in healthy young women. Lipid Health Dis 2010;9:103.
    • 102. Kotani K, Yamada S, Yamada T, Taniguchi N, Sakurabayashi I. The relationship between oxidized lipoprotein(a) and carotid atherosclerosis in asymptomatic subjects: a comparison with native lipoprotein(a). Lipids Health Dis 2011;10:174.
    • 103. Kotani K, Yamada S, Yamada T, Kario K, Taniguchi N. Oxidized lipoprotein(a) and cardio-ankle vascular index (CAVI) in hypertensive subjects. Heart Vessel 2013;28:461-6.
    • 104. Kotani K, Sakane N. Carotid Intima-Media Thickness in Asymptomatic Subjects With Low Lipoprotein(a) Levels. J Clin Med Res 2012;4:130-4.
    • 105. Kiechl S, Willeit J, Mayr M, Viehweider B, Oberhollenzer M, Kronenberg F, et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol 2007;27:1788-95.
    • 106. Ishikawa S, Kotani K, Kario K, Kayaba K, Gotoh T, Nakamura Y, et al. Inverse association between serum lipoprotein(a) and cerebral hemorrhage in the Japanese population. Thromb Res 2013;131:e54-8.
    • 107. Tanaka T, Okamura T. Blood cholesterol level and risk of stroke in community-based or worksite cohort studies: a review of Japanese cohort studies in the past 20 years. Keio J Med 2012;61:79-88.
    • 108. Lippi G. Lipoprotein(a)-lowering therapies: A double edged sword? Atherosclerosis 2015;242:504-5.
    • 109. Bergmark C, Dewan A, Orsoni A, Merki E, Miller ER, Shin MJ, et al. A novel function of lipoprotein(a) as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res 2008;49:2230-9.
    • 110. Hsieh Wu J. Lipoprotein(a) in vascular disease, cancer and longevity. Chang Gung Med J 2011;34:555-64.
    • 111. Trieu VN, Uckun FM. Apolipoprotein(a), a link between atherosclerosis and tumor angiogenesis. Biochem Biophys Res Commun 1999;257:714-8.
    • 112. Kim JS, Chang JH, Yu HK, Ahn JH, Yum JS, Lee SK, et al. Inhibition of angiogenesis and angiogenesis-dependent tumor growth by the cryptic kringle fragments of human apolipoprotein(a). J Biol Chem 2003;278:29000-8.
    • 113. Panza F, D'Introno A, Capurso C, Colacicco AM, Seripa D, Pilotto A, et al. Lipoproteins, vascular-related genetic factors, and human longevity. Rejuvenation Res 2007;10:441-58.
    • 114. Sawabe M, Tanaka N, Mieno MN, Ishikawa S, Kayaba K, Nakahara K, et al. Low lipoprotein(a) concentration is associated with cancer and all-cause deaths: a population-based cohort study (the JMS cohort study). PloS One 2012;7:e31954.
  • Inferred research data

    The results below are discovered through our pilot algorithms. Let us know how we are doing!

    Title Trust
    69
    69%
  • No similar publications.

Share - Bookmark

Cite this article